Subvisible 577nm pascal macular laser with endpoint management in diabetic macular edema

Session Details

Session Title: Free Paper Session 5: Anterior/Posterior Segment Surgery

Session Date/Time: Thursday 07/09/2017 | 11:00-12:30

Paper Time: 11:18

Venue: Room 117

First Author: : W.Abdul Aziz UK

Co Author(s): :    A. Jameel   J. Ho   M. Muqit                       

Abstract Details


To investigate the effects of pattern scanning laser (Pascal®) 577nm subvisible macular laser with endpoint management (ML-EpM) on vision and central macular thickness in eyes with diabetic macular edema (DME).




Single-centre retrospective evaluation of Pascal® ML-EpM treatment in DME. 37 patients with DME were treated using barely-visible laser target burns, and then subvisible EpM applied to multispot arrays.LogMAR visual acuity (VA) and central subfield retinal thickness (CRT) on OCT were recorded at baseline, 3, 6, 9, and 12 months post-laser treatment. DME regression was assessed by clinical assessment, laser re-treatments and/or intravitreal injection therapy. The main outcome measures are CRT and LogMAR vision.


Thirty-seven eyes of 32 patients were studied between September 29th 2014 and July 1st 2016.The ML-EpM was performed using 10ms, 100μm spot, and mean power of 44mW (42-45mW) with EpM 35%.Baseline VA was logMAR 0.23 with no significant change at 12-month follow-up (logMAR 0.26).There was a significant reduction in mean CRT after EpM (-57μm at 6 months; -46μm at 9 months; p<0.05).There was a favorable response for DME treatment with clinical regression for 22 eyes.


We report favorable responses on macular thickness and clinical effectiveness, with no adverse outcomes from using subvisible 10ms macular laser treatment in DME.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email:

Privacy policyHotel Terms and Conditions Cancellation policy